Applies to Employer plans.
Depends on your plan's benefitCovered only for select plans with specific benefit language allowing coverage of drugs for weight loss management or weight-related comorbidities; drugs for weight loss management are a standard exclusion for most benefit plans
Qualification pathways
You can qualify through any one of these.
CV Risk Reduction - Continuation/Already on therapy
All of:
- Patient is 18 years of age or older
- Patient has completed at least 3 months of therapy with Wegovy at a stable maintenance dose
- Patient lost at least 5% of baseline body weight OR has continued to maintain their initial 5% weight loss (documentation required)
- Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
- Patient will NOT be using the requested agent in combination with another targeted weight loss agent
- Patient does not have a diagnosis of diabetes mellitus or pancreatitis within 180 days prior to the request
CV Risk Reduction - New to therapy
All of:
- Patient is 18 years of age or older
- Patient has participated in a comprehensive weight management program encouraging behavioral modification, reduced calorie diet and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
- Patient has a baseline BMI ≥ 27 kg/m2
- Patient has established cardiovascular disease defined by previous myocardial infarction, previous stroke, or symptomatic peripheral arterial disease (intermittent claudication with ankle-brachial index <0.85 at rest, peripheral arterial revascularization procedure, or amputation due to atherosclerotic cardiovascular disease) — documentation required
- Patient is receiving and will continue standard of care treatment of cardiovascular disease including a drug from each of: antiplatelet (e.g., aspirin, P2Y12 receptor blocker), lipid-lowering (e.g., statin, ezetimibe, PCSK9 inhibitors), antihypertensive (e.g., beta-blocker, ACE inhibitors or ARBs) unless inadequate response, intolerance, documented contraindication, or medically justifiable reason to preclude use of all medications in any/all classes — documentation required
- Patient does not have a diagnosis of diabetes mellitus or pancreatitis within 180 days prior to the request
- Patient is currently on and will continue to be on a weight loss regimen of reduced calorie diet, increased physical activity, and behavioral modifications
- Patient will NOT be using the requested agent in combination with another targeted weight loss agent
Documentation to bring
- Chart notes or medical record documentation of Body Mass Index (BMI)
- Chart notes, medical record documentation, or claims history supporting established cardiovascular disease (i.e., previous myocardial infarction, previous stroke, or symptomatic peripheral arterial disease)
- Documentation of current standard of care treatment of cardiovascular disease including antiplatelet, lipid-lowering, and antihypertensive therapy (or clinical reason any class is not appropriate)
- Documentation confirming no diagnosis of diabetes mellitus or pancreatitis within 180 days prior to the request
- Documentation of at least 5% baseline body weight loss or maintained 5% weight loss (for continuation)
Quantity limits
- All strengths — 4 pens
Approval and renewal
- Initial approval: 6 months
- Renewal: every 12 months
- Renewal: Lost at least 5% of baseline body weight OR maintained initial 5% weight loss after at least 3 months at stable maintenance dose.
- Renewal: At least 12 weeks on therapy before the first renewal.
Not covered when
- Diagnosis of diabetes mellitus within 180 days prior to the request
- Diagnosis of pancreatitis within 180 days prior to the request
- Combination use with another targeted weight loss agent
- Plans without specific benefit language allowing weight loss drug coverage
Policy note: GDMT classes required are antiplatelet (e.g., aspirin, P2Y12 receptor blocker), lipid-lowering (e.g., statin, ezetimibe, PCSK9 inhibitors), and antihypertensive (e.g., beta-blocker, ACE inhibitors, or ARBs). Exceptions allowed for inadequate response, intolerance, documented contraindication, or medically justifiable reason. The 180-day diabetes/pancreatitis exclusion window applies to the initial approval pathway; the continuation pathway also requires 5% weight loss maintained at 3 months on stable maintenance dose. Covers Wegovy injection, Wegovy HD injection, and Wegovy tablet. Approval duration stated as 6 months for initial for 'weight loss and cardiovascular risk reduction' combined.
Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs For Weight Loss Management · View policy document (PDF)